News

FDA slams Soon-Shiong, ImmunityBio for 'misleading' drug claims

Regulatory 72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
July 29, 2026↗ source

The FDA issued a warning letter to ImmunityBio and founder Patrick Soon-Shiong for making false and misleading claims regarding their cancer therapy, Anktiva. The agency criticized the company for suggesting the drug treats 'all cancers' without evidence, failing to disclose required combination use with a vaccine, and downplaying serious risks. The FDA also challenged claims that the treatment renders patients 'cancer free,' stating that such assertions are not supported by clinical data.

Related peptides

BINA
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.